Senti co-founders describe tunable CAR T system
A study led by Senti Biosciences Inc. (South San Francisco, Calif.) Scientific co-Founder Wilson Wong describes a CAR T cell system that uses protein-based linkers to recognize tumor antigens instead of a fixed chimeric antigen receptor, culminating in a more flexible cell therapy that can target multiple antigens. The study in Cell is out of Boston University and Massachusetts Institute of Technology.
Wong is an assistant professor of biomedical engineering at Boston University. Senti, which debuted in February, was also co-founded by study author James Collins, a professor of medical engineering and science at MIT, and CEO Timothy Lu, an associate professor of biological engineering, electrical engineering and computer science at MIT. Senti is developing synthetic biology circuits to control cell and gene therapies (see BioCentury Innovations, Feb. 27)...